景峰医药(000908) - 2021 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2021 was ¥120,869,292.97, a decrease of 60.73% compared to ¥307,774,671.77 in the same period last year[9] - Net profit attributable to shareholders was ¥27,546,229.31, representing a significant increase of 1,894.28% from ¥1,381,264.66 year-on-year[9] - Basic earnings per share rose to ¥0.0313, up 1,856.25% from ¥0.0016 in the same period last year[9] - The total operating costs for Q1 2021 were CNY 188.59 million, a decrease from CNY 309.47 million in the same period last year, representing a reduction of approximately 39%[41] - The net profit for Q1 2021 was CNY 19.20 million, compared to a net loss of CNY 7.44 million in Q1 2020, indicating a significant turnaround[42] - The total profit for Q1 2021 was CNY 21.50 million, compared to a total loss of CNY 2.53 million in Q1 2020, marking a significant improvement[42] - The operating profit for Q1 2021 was CNY 24.80 million, a recovery from an operating loss of CNY 1.66 million in the previous year[42] Cash Flow - The net cash flow from operating activities was ¥122,196,127.27, a decline of 249.25% compared to -¥81,875,651.10 in the previous year[9] - Cash and cash equivalents decreased by 39.73% to ¥98,952,894.06 from ¥164,196,069.51 due to repayment of maturing debts[16] - The total cash inflow from operating activities was CNY 296,548,898.02, an increase of 17.2% compared to CNY 253,053,256.10 in the previous period[50] - The net cash flow from operating activities was CNY 122,196,127.27, a significant recovery from a negative CNY 81,875,651.10 in the previous period[50] - Cash inflow from investment activities totaled CNY 83,318,080.00, compared to CNY 90,157,857.95 in the previous period[50] - The net cash flow from investment activities was CNY 74,233,389.56, recovering from a negative CNY 43,465,996.76[50] - Cash inflow from financing activities was CNY 152,867,000.00, down 41.7% from CNY 262,350,000.00[51] - The net cash flow from financing activities was negative CNY 257,404,227.60, compared to a positive CNY 28,936,944.25 in the previous period[51] - The ending cash and cash equivalents balance was CNY 98,952,894.06, down from CNY 309,724,694.41 in the previous period[51] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,601,147,745.90, down 3.31% from ¥2,690,276,316.02 at the end of the previous year[9] - Total liabilities due within one year increased by 399.12% to ¥476,203,488.07 from ¥95,408,325.32, mainly due to reclassification of bonds[16] - The company's total liabilities decreased from CNY 2,051,835,713.87 to CNY 1,960,961,144.59, a decrease of approximately 4.4%[34] - Current liabilities increased from CNY 1,470,982,182.54 to CNY 1,778,937,711.89, an increase of approximately 20.9%[34] - Non-current liabilities decreased significantly from CNY 580,853,531.33 to CNY 182,023,432.70, a decline of about 68.7%[34] - The total equity attributable to shareholders increased from CNY 442,774,825.95 to CNY 473,658,413.37, an increase of about 6.9%[35] Research and Development - Research and development expenses decreased by 66.52% to ¥8,692,269.11 from ¥25,959,419.27, indicating reduced investment in R&D[16] - The cumulative investment in the new R&D center project reached ¥111,722,000 as of March 31, 2021[22] Shareholder Information - The total number of common shareholders at the end of the reporting period was 64,887[12] - The largest shareholder, Ye Xiangwu, holds 17.75% of the shares, amounting to 156,129,982 shares, with 120,847,486 shares pledged[12] - The company did not engage in any repurchase transactions among the top 10 shareholders during the reporting period[13] Other Financial Metrics - Non-recurring gains and losses totaled ¥89,853,928.15, with government subsidies contributing ¥7,189,937.94 and other non-operating income and expenses at -¥3,299,733.50[10] - Long-term equity investments decreased from CNY 146,761,012.77 to CNY 130,896,186.16, a decline of approximately 10.8%[33] - The company reported a tax expense of CNY 2.30 million for Q1 2021, down from CNY 4.90 million in the same period last year[42] - Other comprehensive income after tax for Q1 2021 was CNY 6.54 million, compared to a loss of CNY 0.12 million in Q1 2020[42] - The company recorded a credit impairment loss of CNY -0.32 million in Q1 2021, a significant improvement from a loss of CNY -9.84 million in Q1 2020[41] - The company has not undergone an audit for the first quarter report[56]